drugset
drugset / Trial / NCT07629557

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

NCT07629557 ↗

Phase 4 Recruiting 15 enrolled Glaukos Corporation
NaSingle-groupOpen-labelTreatment

Summary

Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.

Timeline

Start
2026-05-11
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Riboflavin Other / unclassified — —

Indications

keratoconus